(Q48112332)

8 February 2018

title

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity (English)

1 reference

8 February 2018

0 references

8

Jeffrey Palmer

1 reference

8 February 2018

Krzysztof Selmaj

5

object named as

Krzysztof Selmaj

1 reference

8 February 2018

author name string

Joanne L Jones

1

1 reference

8 February 2018

Jane M Anderson

2

1 reference

8 February 2018

Chia-Ling Phuah

3

1 reference

8 February 2018

Edward J Fox

4

1 reference

8 February 2018

David Margolin

6

1 reference

8 February 2018

Stephen L Lake

7

1 reference

8 February 2018

Sara J Thompson

9

1 reference

8 February 2018

Alastair Wilkins

10

1 reference

8 February 2018

Daniel J Webber

11

1 reference

8 February 2018

D Alastair Compston

12

1 reference

8 February 2018

Alasdair J Coles

13

1 reference

8 February 2018

language of work or name

English

0 references

publication date

21 July 2010

1 reference

8 February 2018

published in

Brain

1 reference

8 February 2018

volume

133

1 reference

8 February 2018

issue

Pt 8

1 reference

8 February 2018

page(s)

2232-2247

1 reference

8 February 2018

The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice

cites work

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factorin situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

Efficient central nervous system remyelination requires T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

Passive or active immunization with myelin basic protein impairs neurological function and exacerbates neuropathology after spinal cord injury in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

Low-dose gamma-irradiation promotes survival of injured neurons in the central nervous system via homeostasis-driven proliferation of T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

Neuroprotective autoimmunity: naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

Myelin specific Th1 cells are necessary for post-traumatic protective autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

A role for fibroblast growth factor in oligodendrocyte development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

FGF modulates the PDGF-driven pathway of oligodendrocyte development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

Gene expression in brain during cuprizone-induced demyelination and remyelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

Platelet-derived growth factor from astrocytes drives the clock that times oligodendrocyte development in culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

Adhesion defects of antibody-mediated target cell binding of neonatal natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

Insulin-like growth factor 1 promotes cord blood T cell maturation and inhibits its spontaneous and phytohemagglutinin-induced apoptosis through different mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

Insulin-like growth factor-1 activates Akt and Jun N-terminal kinases (JNKs) in promoting the survival of T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

Cooperation between PDGF and FGF converts slowly dividing O-2Aadult progenitor cells to rapidly dividing cells with characteristics of O-2Aperinatal progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

Oligodendrocyte precursor cells in the demyelinated multiple sclerosis spinal cord.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

Platelet-derived growth factor promotes division and motility and inhibits premature differentiation of the oligodendrocyte/type-2 astrocyte progenitor ceil

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ176

21 January 2018

Identifiers

DOI

10.1093/BRAIN/AWQ176

1 reference

8 February 2018

1 reference

8 February 2018